ARA-290 (Cibinetide) (10 mg Vial) Dosage Protocol
ARA-290 (cibinetide) is an 11-amino-acid peptide derived from erythropoietin (EPO) that retains tissue-protective and anti-inflammatory effects without erythropoietic activity.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
10 mg vial math anchored to a published human study schedule
Human Study Calculation (2.0 mL = 5 mg/mL)
| Period | Amount per Administration | U-100 Units (mL) |
|---|---|---|
| Days 1–28 | 4 mg (4,000 mcg) | 80 units (0.80 mL) |
Frequency: Once daily by subcutaneous administration in the cited phase 2 study. A separate pilot used 2 mg intravenously three times weekly for four weeks; that route and schedule should not be converted into this subcutaneous U-100 table.
Research reference only: This table converts a published study amount into vial concentration and syringe volume. It is not a prescribing recommendation, and the manufactured clinical-trial formulation is not interchangeable with a third-party research vial.
Reconstitution Steps
- Clean the peptide-vial stopper and diluent-vial stopper with alcohol, then allow both to dry.
- Draw exactly 2.0 mL of bacteriostatic water with a new sterile syringe and inject it slowly down the inside wall of the peptide vial.
- Gently swirl or roll the vial until the contents are dissolved. Do not shake.
- Label the vial with the compound, 5 mg/mL concentration, and preparation date. Store it according to verified product-specific instructions.
Important: This guide is for educational and research calculation purposes only. It is not medical advice or a direction for human use.
Supplies Needed
This worked quantity plan mirrors the 28-day, 4 mg once-daily subcutaneous schedule used in the cited phase 2 study. It is an arithmetic example, not a purchasing or treatment recommendation.
| Item | Quantity |
|---|---|
| Peptide Vials (ARA-290, 10 mg each) | 28 days at 4 mg/day = 112 mg total 112 mg ÷ 10 mg/vial = 11.2, so the calculation requires 12 vials when rounded up to whole vials |
| Insulin Syringes (U-100) | One new syringe per administration 28 days: 28 syringes |
| Bacteriostatic Water (10 mL bottles) | 12 vials × 2.0 mL = 24 mL total Round up to 3 × 10 mL bottles |
| Alcohol Swabs | 28 days × 2 = 56 swabs Round up to 1 × 100-count box |
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 14 days, protect from light |
Important Notes
How This Works
ARA-290 is derived from helix B of EPO and binds the innate repair receptor (IRR — a tissue-protective receptor distinct from EPO's erythropoietic receptor). It produces anti-inflammatory and tissue-protective effects without raising hematocrit.
Potential Benefits & Side Effects
Potential Benefits
- Anti-inflammatory effects via IRR.
- Studied in diabetic neuropathy and sarcoidosis-related neuropathy.
- No erythropoietic effect — separate from EPO's blood effects.
Side Effect Profile
- Generally well-tolerated in trials.
- Mild injection-site reactions.
Lifestyle Factors
- Anti-inflammatory diet complements effects.
- Adequate B-vitamins support nerve health.
Injection Technique
- Subcutaneous, rotate sites.